At NINGBO INNO PHARMCHEM CO.,LTD., we focus on providing critical chemical compounds that drive innovation in pharmaceuticals and research. Crisaborole, also known by its developmental code AN2728 and CAS number 906673-24-3, is a prime example of a compound with significant therapeutic and research value. This topical medication, primarily used for treating atopic dermatitis, showcases the power of targeted therapies like PDE4 inhibitors. Understanding the AN2728 mechanism of action and its precise chemical profile is fundamental to its application.

Crisaborole's chemical structure, a benzoxaborole derivative, confers its unique PDE4 inhibitory properties. The efficacy of Crisaborole in clinical settings has been rigorously tested, and insights from these crisaborole clinical trials are invaluable for researchers. The compound's ability to modulate inflammatory pathways by inhibiting PDE4 makes it a key player in dermatological research and treatment development. The focus on a topical PDE4 inhibitor approach offers targeted benefits with reduced systemic exposure compared to oral medications.

The development and widespread use of drugs like Crisaborole necessitate a strong emphasis on the quality and purity of the chemical ingredients. NINGBO INNO PHARMCHEM CO.,LTD. specializes in supplying high-grade intermediates and reference standards, ensuring that researchers and manufacturers have access to reliable materials. For those involved in drug discovery and quality control, buying pharmaceutical reference standards like Crisaborole is a non-negotiable step in ensuring product integrity and regulatory compliance.

Our commitment extends beyond just supplying chemicals; we aim to be a partner in scientific advancement. By providing detailed information on the chemical profile, research applications, and supporting materials for compounds like Crisaborole, we empower our clients to push the boundaries of innovation. NINGBO INNO PHARMCHEM CO.,LTD. is proud to contribute to the development of novel therapies that improve patient outcomes, reinforcing our role as a key supplier in the global pharmaceutical supply chain.